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Abstract
Background: X-linked adrenoleukodystrophy (ALD) is a metabolic, peroxisomal disease that results from a mutation in the
ABCD1 gene. The most severe course of ALD progression is the cerebral inflammatory and demyelinating form of the
disease, cALD. To date there is very little information on the cytokine mediators in the cerebral spinal fluid (CSF) of these
boys.
Methodology/Principal Findings: Measurement of 23 different cytokines was performed on CSF and serum of boys with
cerebral ALD and patients without ALD. Significant elevations in CSF IL-8 (29.362.2 vs 12.861.1 pg/ml, p=0.0001), IL-1ra
(166630 vs 8.666.5 pg/ml, p=0.005), MCP-1 (610647 vs 328634 pg/ml, p=0.002), and MIP-1b (14.261.3 vs 2.061.4 pg/ml,
p,0.0001) were found in boys with cALD versus the control group. The only serum cytokine showing an elevation in the ALD
group was SDF-1 (21246155 vs 11756125 pg/ml, p=0.0001). The CSF cytokines of IL-8 and MCP-1b correlated with the Loes
MRI severity score (p=0.04 and p=0.008 respectively), as well as the serum SDF-1 level (p=0.002). Finally, CSF total protein
was also significantly elevated in boys with cALD and correlated with both IL-8, MCP-1b (p=0.0001 for both), as well as Loes
MRI severity score (p=0.0007).
Conclusions/Significance: IL-8, IL-1ra, MCP-1, MIP-1b and CSF total protein were significantly elevated in patients with
cALD; IL-8, MCP-1b, and CSF total protein levels correlated with disease severity determined by MRI. This is the largest report
of CSF cytokine levels in cALD to date, and identification of these key cytokines will provide further insight into disease
progression and perhaps lead to improved targeted therapies.
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Introduction
Adrenoleukodystrophy (ALD) is a peroxisomal disease affecting
the nervous system, adrenal cortex, and testis resulting from a
mutation in the ABCD1 gene in humans with a disease prevalence
of approximately 1 in 20,000 [1,2]. The ABCD1 gene is located on
the X-chromosome and it encodes the peroxisomal protein ATP-
binding cassette-transporter D1 responsible for the trafficking of
very-long-chain fatty acids (VLCFA), and over 460 different
mutations have been reported [3]. ALD can display several
different phenotypes; these phenotypes include cerebral childhood
adrenoleukodystrophy (cALD), a cerebral juvenile form, a cerebral
adult form, adrenomyloneuropathy (AMN), and isolated Addison’s
disease. Currently, there is no known link between mutation and
phenotypes, making it difficult to predict the possible progression
of the disease for each individual [1]. In cALD, the 5-year survival
rate after first appearance of the clinical onset of cerebral
inflammation is 59% [3].
Current treatments for cALD are sparse. Although a low-fat diet
to reduce VLCFA intake coupled with a lipid supplement known
as Lorenzo’s Oil has shown to normalize VLCFA concentrations
in the blood and perhaps delay the onset of cALD, these
treatments have not demonstrated an effect on the progression of
cerebral inflammation once it has started [4,5]. The only
treatment that has shown to slow the progression of the cerebral
inflammation and demyelination once the clinical onset of cerebral
inflammation has been observed is hematopoietic stem cell
transplant (HSCT) [2,5]. In studies determining the effectiveness
of HSCT, a clear distinction in the long term survival of the
patients was observed between those in the early-stages of cerebral
inflammation versus those with a higher amount of cerebral
inflammation as determined by MRI [2]. Therefore, the earlier
identification of boys who will develop cALD is needed, and we
need to better understand the mediators of neuroinflammation in
cALD in order to determine those that would benefit most from
HSCT.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32218Although cALD is thought to be driven by an infiltrative
neuroinflammatory process, there has not been a comprehensive
analysis of potential inflammatory mediators involved with cALD [6].
Previous work measuring inflammatory cytokines including tumor
necrosis factor-alpha, interleukin-1 beta, interleukin-4, interleukin-6
and interferon-gamma in brain lesions in postmortem samples from
patients with cALD showed that levels cytokine mRNA were lower
than that compared to samples take from patients with multiple
sclerosis and surprisingly more similarto expression levels in control white
matter [7]. Additionally, there have been mixed data on whether TNF-
alpha plays a role in the pathogenesis of cALD, as protein levels have
not been found not to be different in cALD versus control specimens,
although there is some suggestion that there is increased bioactivity of
TNF-alpha in the serum of boys with cALD [8,9].
We have collected a large number of serum and cerebral spinal
fluid (CSF) samples from boys with cALD prior to undergoing
hematopoietic stem cell transplant and performed a comprehen-
sive analysis of multiple of cytokines using a Luminex-based
inflammatory cytokine panel. Identification of the key mediators
will help us better understand the neuroinflammatory process and
perhaps give clues to new targeted therapies.
Methods
CSF and serum samples were evaluated using the 22-plex, human
panel A, (R&D Systems, Minneapolis, MN) measured with the
Luminexsystem(Luminex,Austin,TX)analyzedbyBioplexsoftware
(BioRad, Hercules, CA). This panel is summarized in Table 1 and
includes: ENA-78, bFGF, G-CSF, GM-CSF, IFN-gamma, IL-
1alpha, IL-1beta, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-17,
MCP-1, MIP-1alpha, MIP-1beta, RANTES, TNF-alpha, TPO, and
VEGF. SDF-1alpha was measured by sandwich ELISA (R&D
Systems). All values were interpolated from standard curves
generated with the relevant recombinant human proteins provided
with the commercial kits. Total protein level was determined by the
hospital acute care lab and extracted from the medical chart.
Objectives
To determine which inflammatory cytokines were elevated in the
CSF and plasma of boys with cALD. To determine if inflammatory
cytokine elevation correlated with disease severity shown by MRI.
Participants
Patients with cALD (n=36, median age 8.3 years) had CSF
sampling done 2 to 6 months prior to hematopoietic stem cell
transplant at the University of Minnesota. Control patients (n=22,
median age of 7.4 years for serum and n=25, median age 6.8
years for serum) were those undergoing intrathecal methotrexate
chemotherapy for a prior diagnosis of acute lymphoblastic
leukemia and were at least 3 months into maintenance therapy
and without CSF leukemia. The CSF was withdrawn prior to
administration of methotrexate. Unavailability of ‘‘healthy’’
controls and risk of attaining CSF from healthy children
established these patients as the most appropriate control group
available and has been previously published [10].
Description of Procedures or Investigations undertaken
Boys with cALD were referred to the University of Minnesota
Division of Pediatric Blood and Marrow Transplant as candidates
for hematopoietic stem cell transplantation. They all had an initial
MRI prior to transplant and required sedation. During the sedated
MRI, a lumbar puncture was performed and 3 milliliters of CSF
was obtained and analyzed for protein level, cell count, and
cytokine analysis. The same procure was used to collect the
‘‘control’’ samples except, sedation is not typically done for
children in ALL maintenance therapy. Serum was obtained at the
same time as the CSF.
Table 1. List of inflammatory factors evaluated in CSF and
serum samples.
Cytokine Name Abbreviation
Epithelial derived neutrophil activating peptide 78 or CXCL5 ENA-78
Basic fibroblast growth factor bFGF
Granulocyte colony stimulating factor G-CSF
Granulocyte macrophage colony stimulating factor GM-CSF
Interferon gamma IFN-gamma
Interleukin 1alpha IL-1alpha
Interleukin 2beta IL-1beta
Interleukin 1 receptor antagonist IL-1ra
Interleukin 2 IL-2
Interleukin 4 IL-4
Interleukin 5 IL-5
Interleukin 6 IL-6
Interleukin 8 IL-8
Interleukin 10 IL-10
Interleukin 17 IL-17
Monocyte chemotactic protein 1 or CCL2 MCP-1
Macrophage inflammatory protein 1alpha or CCL3 MIP-1a
Macrophage inflammatory protein 1beta or CCL4 MIP-1b
Regulated upon activation, Normal T-cell expressed or CCL5 RANTES
Tumor necrosis factor alpha TNF-alpha
Thrombopoietin TPO
Vascular endothelial growth factor VEGF
Stromal derived factor 1alpha SDF-1alpha
doi:10.1371/journal.pone.0032218.t001
Figure 1. Serum SDF-1 is elevated in boys with cerebral ALD.
SDF-1 levels were determined by ELISA. Boxes show min and max, and
the bar is at the mean. A Student’s unpaired t-test calculated p-value
shown.
doi:10.1371/journal.pone.0032218.g001
CSF Cytokines in cALD
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This study and the use of all bodily fluids was approved by the
Committee on the Use of Human Subjects in Research at the
University of Minnesota. Informed written consent was obtained
for all patient samples from the parents or guardians on behalf of
the child participants. Patient written assent was also obtained if
patients were greater than 8 years of age.
Statistical methods (if applicable)
Each sample was run in duplicate and an average value
calculated to arrive at the cytokine concentration using standard
curves generated with the relevant recombinant human proteins
provided with the commercial kits. Means for the cALD and
control groups were calculated and subjected to a two-tailed
Student’s t-test to compute a p-value. A linear regression analysis
from cytokines of interest and MRI Loes score was performed
using Prism software (version 5.0b).
Results
We performed a comprehensive evaluation of inflammatory
cytokine levels in the CSF and serum of boys with cALD
summarized in Table 1. Our analysis of serum from control
(n=25, median age 6.8) versus cALD patients (n=36, median age
8.3) showed no significant differences a significant differences
Figure 2. CSF inflammatory cytokines are elevated in boys with cerebral ALD. CSF cytokines were evaluated using a Lumunix system and
SDF-1 by ELISA. Boxes show min and max, and the bar is at the mean. A Student’s unpaired t-test calculated p-values shown.
doi:10.1371/journal.pone.0032218.g002
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pg/ml versus 21246155 pg/ml, respectively, as shown in Figure 1
(p=0.0001). None of the other cytokines in our analysis showed a
significant difference between cALD and control patient serum
(data not shown). Contrary to the serum, Figure 2 shows SDF-1
levels in the CSF were not different between cALD and controls
with 321662.3 pg/ml and 274632.6 pg/ml (p=0.54).
Further cytokine analyses performed on the CSF revealed
higher levels in cALD samples compared to controls for IL-8
(29.362.2 vs 12.861.1 pg/ml, p=0.0001), IL-1ra (166630 vs
8.666.5 pg/ml, p=0.005), MCP-1 (610647 vs 328634 pg/ml,
p=0.002), and MIP-1b (14.261.3 vs 2.061.4 pg/ml, p,0.0001)
as shown in Figure 2. We also found VEGF to be elevated in the
CSF of several of the boys with cALD and very few of the control
patients, but because of the inconsistency in which it appeared, the
means are not statistically significant.
We have recently shown that another marker, chitotriosidase is
elevated in both the serum and the blood in boys with cALD [10].
The serum SDF-1 levels did not correlate with chitotriosidase
levels (data not shown), but of the CSF cytokines, MCP-1 levels did
correlate very well with chitotriosidase activity (p=0.0002)
(Figure 3), leading us to believe that these two inflammatory
proteins could be linked by a pathophysiologic mechanism.
The Loes Score is an MRI-based quantification of the amount
of cerebral involvement based on a point system derived from
location, extent of disease, and the presence of focal and/or global
atrophy that is present in boys with cALD [11]. All boys referred
to our center have an MRI prior to transplant that is scored per
the scale described by Loes et al. Figure 4 shows that serum SDF-1
levels correlate significantly with the pretransplant Loes score
(p=0.003). In evaluation of the CSF cytokines that were elevated
in the CSF of boys with cALD, we found that IL-8 and MCP-1
had a significant correlation with the pretransplant Loes score
(p=0.04 and p=0.008 respectively), while the other cytokines did
not correlate significantly shown in Figure 5.
In a prior report, our institution characterized the CSF total
protein in 25 boys with cALD [12]. Abnormally high values of
CSF total protein were found in a majority of those tested,
particularly from those with more advanced disease (as seen on
MRI). There was no relationship between CSF IgG levels and IQ,
but there was an inverse relationship between CSF myelin basic
protein and IQ. In this current dataset, we again found markedly
high levels of CSF protein (versus controls) as shown in Figure 6
(p,0.0001). And, in fact, the cytokines IL-8 and MCP-1
correlated with elevated CSF protein (Figure 6) although MIP-
1b did not (data not shown). Finally, we also verified that CSF
protein concentration correlated with Loes score as shown in
Figure 6 (p=0.0007, R
2=0.30). These data suggest that the total
protein level by itself can correlate with disease severity/
inflammation, which although intuitive, has not been shown
quantitatively.
Discussion
In this study, we determined that there were significant
elevations in inflammatory cytokine levels in the serum (SDF-1)
and CSF (IL-8, IL-1ra, MCP-1, MIP-1b, and VEGF). The serum
SDF-1and CSF IL-8 and MCP-1 correlated significantly with the
pretransplant MRI Loes score severity and the CSF MCP-1 levels
correlated significantly with chitotriosidase activity. Inflammation
contributes to neuronal death in many inflammatory neurode-
generative disease such as Alzheimer’s disease, multiple sclerosis,
Parkinson’s disease, and amyotrophic lateral sclerosis [13]. All of
the identified cytokines that were elevated in cALD patients have
been implicated to play a role in the regulation of an inflammatory
response that is mediated both by the cells of the immune system
and glial cells. In addition, the fact that TNF-alpha and IL-1 were
not found to be different in our cALD samples correlates with
prior work by McGuiness et al and Philips et al as they also found
no difference in TNF-alpha protein levels in the CSF or serum
from patients with cALD, although McGuiness did find there was
increased TNF-alpha bioactivity in patients with cALD [8,12].
This is the first report of the elevation of SDF-1 in the serum of
patients with cALD. While SDF1 is typically thought of a homing
factor for many cell types [14], it has been shown to be elevated in
patients with various inflammatory diseases such as lupus, multiple
sclerosis, and tick-borne encephalitis [15–17]. In boys with cALD,
we hypothesize that it may reflect a level of chronic inflammation
this exists in these boys. Why SDF1 is only elevated in the serum
and not significantly higher in the CSF, while the opposite is true
Figure 3. Correlation of CSF MCP-1 levels and chitotriosidase
activity. Regression analysis was performed using CSF MCP-1 levels
and CSF chitotriosidase activity as described by Orchard et al [10].
Statistical analysis was performed using Prism software.
doi:10.1371/journal.pone.0032218.g003
Figure 4. Correlation of serum SDF-1 levels and Loes MRI
severity score. Regression analysis was performed using serum SDF-1
levels and each patient’s pretransplant Loes score using Prism software.
doi:10.1371/journal.pone.0032218.g004
CSF Cytokines in cALD
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is being secreted by damaged cells in an unappreciated niche
responding to VLCFA toxicity, which in the case of ALD could be
the adrenal gland, but this, thus far, remains speculative.
MIP-1b (CCL4), IL-8 (CXCL8), and MCP-1 (CCL2) have all
been identified as pro-inflammatory chemokines and can induce
the migration of leukocytes to a desired site and have also been
implicated in other inflammatory diseases such as multiple
sclerosis, Alzheimer’s disease, and HIV [18,19]. MIP-1b is a
chemoattractant for several immune response mediator cells
including natural killer cells and monocytes, and MIP-1b mRNA
has been shown to be increased in the inflammatory areas of
brains affect by cALD [3]. In mouse models, IL-8 plays a role in
leukocyte activation and chemotaxis and has been shown to
provoke polymorphonuclear leukocyte recruitment that is corre-
lated with the breakdown of the blood-brain barrier [18]. We
speculate that IL-8 mediated destruction of the blood-brain-
barrier may explain, in part, the findings of gadolinium
enhancement (a sign of inflammation) seen on the MRI of boys
with cALD. MCP-1 recruits monocytes via chemotaxis to sites of
inflammation and has been identified to play a possible role in the
other aforementioned neurodegenerative diseases [19].
Our finding that MCP-1 levels correlate with chitotriosidase
activity is intriguing as chitotriosidase is a chitolytic enzyme
produced by activated monocytes/macrophages and has been
used as a biomarker in other storage diseases [20,21]. Historically,
Figure 5. Correlation of CSF inflammatory cytokine levels and Loes MRI severity score. Regression analysis was performed using the
previously determined CSF cytokine levels and each patient’s pretransplant Loes score using Prism software.
doi:10.1371/journal.pone.0032218.g005
CSF Cytokines in cALD
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predominately a lymphocytic infiltrate rather than monocytic.
With an increase in both chitotriosidase and MCP-1 (which can be
produced by glial cells as well [22]), this may reflect monocyte/
macrophage activation which has been shown in other inflamma-
tory conditions [21,23]. Alternatively, chitotriosidase could be
originating from microglial cells which are known to be in an
activated, and even apoptotic, state in cALD [23,24]. Is unlikely
that any cells in the CSF are producing chitotriosidase or any of
the other cytokines studied here as the lumbar almost always zero
white blood cells present (data not shown).
An antagonist of the biologic activity of IL-1, IL-1ra is elevated
in many other conditions such inflammatory arthritis (reviewed by
Arend [25]), so our finding of its elevation in the setting of cALD is
not surprising. Whether it plays a key role in the pathogenesis of
cALD or is serving only as a marker is unknown and worthy of
further exploration.
We were able to show that serum SDF-1 and CSF IL-8 and
MCP-1 significantly correlated with disease severity as determined
by MRI. This seems logical that more damage seen on MRI would
be associated with higher cytokine levels. Because of the large
range of values in the paitients with cALD, they are not likely to be
used as biomarkers alone. And the above analysis does not allow
for conclusion about whether these cytokines cause the neuroin-
flammation or if they are elevated as a result of an untempered
inflammatory response preceded by neuronal apoptosis initiated
by VLCFA accumulation. These results, nonetheless, could show
promise as early indicators for cerebral inflammation in ALD
patients if measured prospectively. This is important because
studies have shown that HSCT is significantly more effective if
performed during the early stages of cerebral inflammation and
the outcomes are improved [2,5,26,27].
The finding of elevated CSF total protein levels in boys with
cALD has been suggested in a prior study from our institution
[12]. The fact that IL-8 and MCP-1 levels also correlated with
CSF protein concentration is not surprising, but should not
undermine the importance of the increased amounts of these
cytokines because cells can respond to the local concentration
gradient of these factors regardless of other protein content.
Increased total protein in the CSF agrees with the inflammatory
nature of cALD, and the correlation of total CSF protein with the
Loes score is an interesting finding and confirms the prior report
quantitatively. What is not known is the total makeup of the CSF
protein. While CSF is known to contain immunoglobulin, myelin
basic protein, as well as the cytokines described in this study, there
are assuredly many other factors which may play a role in the
pathophysiology of cALD which are currently being explored.
In this study, we have identified key cytokines that are found at
elevated levels in the serum and CSF of boys with cALD in the
largest cohort described to date. These factors could be possible
therapeutic targets for future clinical interventions to halt the
progression of the cALD. Finally, while dietary modifications or
supplements may be attempted to prevent the onset of
neurological symptoms, the only modality successful at slowing
disease progression is HSCT. It is possible that the cytokines
identified in this study may help, when combined with other
Figure 6. Elevated levels of CSF total protein correlate to IL-8, MCP-1, and Loes MRI severity score. CSF total protein levels were taken
from the patients’ medical record. Boxes show min and max, and the bar is at the mean. Regression analysis was performed using the previously
determined CSF cytokine levels for IL-8 and MCP-1 as well as each patient’s pretransplant Loes score using Prism software.
doi:10.1371/journal.pone.0032218.g006
CSF Cytokines in cALD
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as this can be difficult on an individual patient basis.
Limitations
Ethically obtaining ideal control CSF samples was a challenge
for this study. We used CSF from children who were receiving
maintenance therapy for their acute lymphoblastic leukemia (and
were in remission) as they were having routine spinal taps every 3
months. The main concern was possibly selecting children as
control patients with suppressed CSF cytokines thereby skewing
the data, but studies measuring cytokine levels in CSF of healthy
children yielded very comparable results to our data, supporting
that the cytokine levels in our control patients in this study are
congruent with accepted values in the literature [28,29].
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